FDA Highlights Benefits OTC Monograph User Fees Could Deliver
This article was originally published in The Pink Sheet Daily
FDA schedules public meeting June 10 and opens a docket for stakeholder input on potential development of a user fee program for OTC monograph drugs. The OTC monograph is "one of the largest and most complex regulatory programs ever undertaken at FDA."
Register for our free email digests: